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Idiopathic mast cell activation syndrome can be a rare cause for chronic abdominal 
pain in children. It remains a diagnosis by exclusion that can be particularly challenging 
due to the vast variety of possible clinical manifestations. We present a 13-year-old boy 
who suffered from a multitude of unspecific complaints over a long period of time. In 
this case, an assessment of mast cell-derived metabolites and immunohistochemical 
analysis of bioptic specimen was worthwhile. After ruling out, primary (oncologic) and 
secondary causes for mast cell activation, pharmacologic treatment adapted to the 
patient’s salicylate intolerance resulted in a major relief of symptoms.
Keywords: idiopathic mast cell activation syndrome, mast cell activation, salicylate intolerance, mastocytosis, 
endoscopically guided lavage, abdominal pain
BaCKGRoUND aND Case pReseNtatIoN
Chronic abdominal pain in children and adolescents is a common cause for medical consultations 
and can be associated with other non-specific symptoms such as headaches and nausea. Even if 
no organic cause is obvious in routine examination and laboratory checkup, sometimes a more 
profound investigation can be worthwhile.
A 13-year-old male adolescent presented with a history of suffering from paroxysmal spas-
modic bowel pain, nausea, dizziness, headaches, and hot flashes for a period of over 2 years. Due 
to his complaints he missed over 12 weeks of school and also reported a loss of sleep. The family 
was not aware that the symptoms were associated with any certain circumstances or a particular 
diet. Preceding explorations for basic laboratory blood analysis, celiac serological testing, stool 
examination for bacteria, parasites, and chronic inflammatory bowel disease (repeatedly erythro-
cyte sedimentation rate, C reactive protein, and fecal calprotectin), allergy checkup (serological 
IgE-RAST for foods and skin Prick testing), abdominal and cardiac ultrasound, electroencepha-
lography, and cranial MRI imaging were without pathological findings. Two previous gastric 
endoscopies only found a minor unspecific gastritis without evidence for a Helicobacter pylori 
infection, and it was treated with proton pump inhibitors without any reported improvement of 
symptoms. Intestinal carbohydrate malabsorption (fructose, lactose, and sorbitol breath tests) 
was excluded. A symptom diary finally showed an association to the consumption of cheese and 
chocolate, possibly hinting at histamine intolerance. Furthermore, the patient reported a slight 
Abbreviations: MCA, mast cell activation; IMCAS, idiopathic mast cell activation syndrome; CD117, tyrosine kinase c-KIT; 
TNFα, tumor necrosis factor alpha; ESR, erythrocyte sedimentation rate; CrP, C reactive protein; PGD2, prostaglandin; FET, 
functional eicosanoid test; MCT, mast cell tryptase.
FIGURe 1 | Macroscopic findings in gastroscopy and colonoscopy. Follicular hyperplasia in upper and lower intestinal tract.
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relief of symptoms while implementing a histamine-reduced 
diet, thus a double-blind placebo controlled food challenge for 
histamine was planned. Salicylate intolerance was suspected 
due to reported complaints and diagnosed by implementing an 
extended functional eicosanoid test determining the release of 
the eicosanoids leukotrienes and prostaglandines after in vitro 
exposure to salicylates.
Although levels for tryptase (2.7 µg/L) were in normal range, 
repeatedly elevated serum tumor necrosis factor alpha (TNFα) 
ranging from 10.5 to 27.7  pg/mL (ref. <8.1  pg/mL) as well as 
significantly enhanced excretion of methylhistamine (17.8  µg/
mmol crea/m2 BSA; ref. value <6.5  µg/mmol crea/m2 BSA) in 
a 24 h urine sample indicating a state of high endogenous hista-
mine production (1). The endoscopic evaluation macroscopically 
showed nodular hyperplastic spots particularly in the gastric 
antrum and terminal ileum (Figure  1). Hematoxylin–eosin 
stains from upper and lower GI tract revealed duodenal, ileal, and 
colonic lymphoplasmacytic infiltration, but no signs of erosive 
inflammation or epithelial damage. Again, an infection with 
H. pylori was histologically ruled out in the biopsy specimen of the 
gastric antrum. Immunhistochemically, up to 60 tissue mast cells 
per high power field with normal morphology were detected (no 
immature cell forms or spindle shapes, CD117+, MCT+, CD25−, 
and c-KIT D816V negative; Figure 2). In a segmental endoscopi-
cally guided lavage from the lower GI tract, a significant intestinal 
(local) IgE secretion specific to common food antigens was not 
detected, but histamine degradation capability was found to be 
modestly reduced in all specimen (Table S1 in Supplementary 
Material) (2).
Since all diagnostic criteria for idiopathic mast cell activation 
syndrome (IMCAS) as suggested by Akin et  al. (3) and Valent 
et  al. (4) were met (Table  1), the patient received nutritional 
counseling to avoid histamine and salicylate rich foods and oral 
treatment with histaminic receptor blockers (ketotifen 1× 1 mg), 
a leukotriene antagonist (montelukast 1× 4 mg), and slow-release 
vitamin C (1× 500  mg) to inhibit mast cell degranulation (5). 
A possible treatment option with cromoglicic acid was avoided 
due to intolerance to salicylates. Melatonin 2 mg was given orally 
to treat sleep disturbances.
Under this regime, the patient experienced a major improve-
ment of complaints, no side effects were observed. Administering 
medication before going to sleep averted a possible ketotifen-
associated fatigue.
DIsCUssIoN
Idiopathic mast cell activation syndrome is a relatively “new” dis-
order as it was first described in 2010 (3, 4). It is used to describe 
symptoms caused by mast cell activation (MCA) that cannot be 
explained by an underlying allergic or inflammatory condition 
and do not fulfill the WHO criteria for oncologic conditions 
such as systemic or cutaneous mastocytosis (6, 7). The latter are 
rare diseases that involve clonal expansion of mutated stem cells 
and are not to be confused with IMCAS. Therefore, a thorough 
clinical examination for urticarial pigmentosa as an indicator for 
cutaneous mastocytosis and laboratory assessment for elevated 
tryptase levels (particularly >20 ng/mL), CD2, CD25 expression 
and c-KIT_D816V mutation in mast cell infiltrates is essential 
(6, 7). In bioptic tissue specimen of IMCAS multifocal, dense 
infiltrations with atypical morphology, immature, or spindle 
shaped mast cells should not be present. In case of uncertainty 
weather an underlying clonal disease is present bone marrow 
taBle 1 | Diagnostic criteria for idiopathic mast cell activation syndrome.a
all four criteria must be fulfilled
 1. Episodic symptoms consistent with mast cell mediator release affecting ≥2 
organ systems (skin, gastrointestinal, cardiovascular, respiratory, naso-ocular, 
and neuropsychiatricb)
 2. Response of clinical symptoms to histamine receptor blockers or mast cell 
targeting agents
 3. Evidence of an increase in validated urinary or serum markers of mast cell 
activation (MCA)
 4. Rule out of primary (oncologic) and secondary causes of MCA
aSlightly abbreviated and modified from the original versions by Akin et al. (3) and Valent 
et al. (4).
bTypical symptoms, e.g., flushing, pruritus, urticaria, angioedema, nasal congestion 
and conjunctival injections, arterial hypotension and tachycardia, syncope, diarrhea, 
abdominal cramping, headaches, fatigue, and pulmonary wheezing.
FIGURe 2 | Immunohistochemical findings demonstrating mature mast cell infiltration. Dense stromal mast cell infiltrations of up to 60/HPF [staining for CD117+ 
(left), tryptase (right), and CD25− (lower left image)]; mature type; cKIT-D816V mutation negative; normal crypt architecture; no eosinophils.
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biopsy and molecular genetic analysis for c-Kit mutations should 
be considered.
Idiopathic mast cell activation syndrome remains a diagno-
sis by exclusion that can be very challenging to assess due to 
multitude of possible clinical manifestations of symptoms and 
etiologies leading to MCA. Clinical symptomatology is derived 
from an increase of mast cell mediators and can be classified to 
organ systems (Table 1). In a state of increased MCA, an eleva-
tion of validated markers such as serum tryptase, TNFα, 24-h 
urine histamine metabolites, PGD, or 11-β-prostaglandin F2 are 
essential for diagnostic approach (3, 4). The difficulty to diagnose 
IMCAS is to demonstrate signs of definitive MCA while exclud-
ing secondary etiologies explaining mast cell involvement such as 
allergy, infection, autoimmunity, and tumors.
In our case, a segmental endoscopically guided lavage from 
the lower GI tract was made to detect local IgE production. This 
enabled us to exclude local seronegative food allergy as a relevant 
cause of mast cell accumulation and activation.
The treatment options for IMCAS include the avoidance of 
identifiable triggers for mast cell degranulation, histamine recep-
tor antagonists, mast cell stabilizing substances such as cromoglicic 
acid, leukotriene receptor blockers, possibly glucocorticoids, and 
slow-release vitamin C (inhibition of mast cell degradation and 
activation of histamine degradation) (8). Response to pharmaco-
logic treatment also is a diagnostic criterion for IMCAS (Table 1).
Salicylate intolerance refers to an altered metabolism of 
arachidonic acid and eicosanoids leading to a predominance 
of leukotrienes over prostaglandins. The main subgroups of 
eicosanoids—the leukotrienes and the prostanoids with the 
prostaglandins and thromboxanes—are predominantly formed 
by the lipoxygenases and the cyclooxygenases, respectively. In 
intolerant individuals, activation of mast cells, basophiles and 
eosinophils, macrophages, platelets, and lymphocytes is common 
and well described (9). The pattern of symptoms may depend on 
location, relative numbers of the responsible cells, and mainly 
on the activation state of mast cells (10). As activated mast 
cells primarily express formation of eicosanoids after contact 
with salicylates besides histamine release and other mediators, 
salicylate intolerance may give a phenotypic advice for a possible 
underlying IMCAS.
CoNClUDING ReMaRKs
In summary, especially for children with a long history of MCA-
compatible symptoms, IMCAS must be considered after ruling 
out chronic inflammatory bowel disease or other primary and 
secondary causes. As IMCAS seems to be underdiagnosed for 
adults probably due to overlaps with irritable bowel diseases and 
4Rechenauer et al. IMCAS and Chronic Abdominal Pain in Children
Frontiers in Pediatrics | www.frontiersin.org March 2018 | Volume 6 | Article 73
fibromyalgia, the diagnosis for children is currently even scarcer. 
In fact, this might be one of the first case reports for salicylate 
intolerance and IMCAS in children.
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